Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Haleon plc is a leading global consumer healthcare company, specializing in over-the-counter products such as pain relief, oral health, and respiratory health. With a strong portfolio including brands like Sensodyne and Panadol, Haleon operates primarily in North America and Europe, leveraging its extensive distribution network and brand recognition to maintain competitive advantages.
Haleon generates revenue through the sale of consumer healthcare products, focusing on high-margin segments. The company benefits from strong brand loyalty and pricing power, particularly in its established markets, allowing it to maintain healthy gross margins of 63.3%.
Changes in consumer health trends impacting demand for OTC products
Regulatory changes affecting product approvals and market access
Competitive dynamics within the consumer healthcare sector
Currency fluctuations impacting international sales
Regulatory changes that could impact product formulations or market access
Technological disruption in consumer healthcare delivery methods
Increased competition from generic brands and private labels
Market share loss to innovative new entrants
Moderate debt levels that could impact financial flexibility in downturns
Potential pension obligations affecting cash flow
moderate - Haleon's performance is somewhat tied to consumer spending patterns, which can be influenced by economic cycles.
Interest rates affect consumer spending and borrowing costs, which can indirectly impact demand for Haleon's products, though the company is less sensitive compared to capital-intensive sectors.
minimal - Haleon operates with a manageable debt-to-equity ratio of 0.52, indicating solid financial health.
value - investors may be drawn to Haleon for its stable cash flow and dividend yield.
moderate - the stock has shown volatility, with a 1-year return of -15.1%, indicating sensitivity to market conditions.